Abstract |
Standard initial therapy for patients with pure and mixed anaplastic oligodendrogliomas (AO/ MAO) includes chemotherapy and radiation therapy. Anaplastic oligodendrogliomas with 1p/19q co-deletion are more responsive to chemotherapy. There is concern for potential long-term CNS toxicity of radiation. Hence an approach using chemotherapy initially and reserving radiation for progressive disease is attractive. This multicenter phase II trial included patients with newly diagnosed AO/ MAO with central pathology review and 1p/19q assay. Temozolomide was given 150 mg/m(2) days 1-7 and 15-21, every 28 days for 8 cycles. The primary endpoint was progression free survival (PFS). Secondary endpoints included response rate, overall survival (OS), treatment toxicity and health-related quality of life (HRQL). Data from 62 patients enrolled between December 2001 and April 2007 at seven centers were analyzed. Among patients with measurable disease, 8 % achieved complete remission, 56 % had stable disease and 36 % had progression. The median PFS and OS were 27.2 months (95 % CI 11.9-36.3) and 105.8 months (95 % CI 51.5-N/A), respectively. Both 1p loss and 1p/19q co-deletion were positive prognostic factors for PFS (p < 0.001) and OS (p < 0.001); and there was some suggestion that 1p/19q co-deletion also predicted better response to chemotherapy (p = 0.007). Grade 3/4 toxicities were mainly hematological. Significantly improved HRQL in the future uncertainty domain of the brain cancer module was seen after cycle 4 (p < 0.001). This trial achieved outcomes similar to those reported previously. Toxicities from dose-intense temozolomide were manageable. Improvement in at least one HRQL domain increased over time. This trial supports the further study of first-line temozolomide monotherapy as an alternative to radiation therapy for patients with newly diagnosed AO/ MAO with 1p 19q co-deleted tumors.
|
Authors | Manmeet S Ahluwalia, Hao Xie, Saurabh Dahiya, Nooshin Hashemi-Sadraei, David Schiff, Paul G Fisher, Marc C Chamberlain, Susan Pannullo, Herbert B Newton, Cathy Brewer, Laura Wood, Richard Prayson, Paul Elson, David M Peereboom |
Journal | Journal of neuro-oncology
(J Neurooncol)
Vol. 122
Issue 1
Pg. 111-9
(Mar 2015)
ISSN: 1573-7373 [Electronic] United States |
PMID | 25534576
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Dacarbazine
- Temozolomide
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Alkylating
(therapeutic use)
- Brain Neoplasms
(drug therapy, genetics, mortality, pathology)
- Chromosome Deletion
- Chromosomes, Human, Pair 1
(genetics)
- Chromosomes, Human, Pair 19
(genetics)
- Dacarbazine
(analogs & derivatives, therapeutic use)
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Neoplasm Grading
- Oligodendroglioma
(drug therapy, genetics, mortality, pathology)
- Patient Outcome Assessment
- Prognosis
- Quality of Life
- Survival Rate
- Temozolomide
- Young Adult
|